Intelligent Bio Solutions completes precision testing for FDA 510(k) submission for codeine detection

INTELLIGENT BIO SOLUTIONS INC.

Precision testing included over 1,600 tests across three production runs and three independent sites.
Results confirmed repeatable, reproducible performance, strengthening the FDA 510(k) submission package.
Submission targets U.S. market clearance for the Intelligent Fingerprinting Drug Screening System for opiate codeine.
Company plans U.S. launch after FDA 510(k) clearance, citing a multi-billion-dollar annual drug screening market.
CEO Harry Simeonidis stated the testing puts the company firmly on track for submission and launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.